CA2424255A1 - Immunotoxines - Google Patents

Immunotoxines Download PDF

Info

Publication number
CA2424255A1
CA2424255A1 CA002424255A CA2424255A CA2424255A1 CA 2424255 A1 CA2424255 A1 CA 2424255A1 CA 002424255 A CA002424255 A CA 002424255A CA 2424255 A CA2424255 A CA 2424255A CA 2424255 A1 CA2424255 A1 CA 2424255A1
Authority
CA
Canada
Prior art keywords
immunotoxin
eta
tumor
cam
4d5mocb
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002424255A
Other languages
English (en)
Inventor
Claudio Di Paolo
Jorg Willuda
Susanne Kubetzko
Ikar Lauffer
Dominique Tschudi
Robert Waibel
Andreas Pluckthun
Rolf A. Stahel
Uwe Zangemeister-Wittke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CA002424255A priority Critical patent/CA2424255A1/fr
Publication of CA2424255A1 publication Critical patent/CA2424255A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CA002424255A 2003-03-26 2003-03-26 Immunotoxines Abandoned CA2424255A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA002424255A CA2424255A1 (fr) 2003-03-26 2003-03-26 Immunotoxines

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA002424255A CA2424255A1 (fr) 2003-03-26 2003-03-26 Immunotoxines

Publications (1)

Publication Number Publication Date
CA2424255A1 true CA2424255A1 (fr) 2004-09-26

Family

ID=33034986

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002424255A Abandoned CA2424255A1 (fr) 2003-03-26 2003-03-26 Immunotoxines

Country Status (1)

Country Link
CA (1) CA2424255A1 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014166002A1 (fr) * 2013-04-12 2014-10-16 Viventia Bio Inc. Compositions et procédés de détection et de traitement de carcinome hépatocellulaire
US20150018526A1 (en) * 2004-03-19 2015-01-15 Merck Patent Gmbh Cytotoxins comprising modified bouganin toxin for the treatment of cancer
US9822182B2 (en) 2013-10-02 2017-11-21 Viventia Bio Inc. Anti-EPCAM antibodies and methods of use
US10576163B2 (en) 2015-03-12 2020-03-03 Viventia Bio Inc. Methods of treatment for EpCAM positive bladder cancer
US10583198B2 (en) 2015-03-12 2020-03-10 Viventia Bio Inc. Dosing strategies for targeting EPCAM positive bladder cancer
US10858429B2 (en) 2003-04-30 2020-12-08 University Of Zurich Methods for treating cancer using an immunotoxin

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10858429B2 (en) 2003-04-30 2020-12-08 University Of Zurich Methods for treating cancer using an immunotoxin
US20150018526A1 (en) * 2004-03-19 2015-01-15 Merck Patent Gmbh Cytotoxins comprising modified bouganin toxin for the treatment of cancer
WO2014166002A1 (fr) * 2013-04-12 2014-10-16 Viventia Bio Inc. Compositions et procédés de détection et de traitement de carcinome hépatocellulaire
CN105188762A (zh) * 2013-04-12 2015-12-23 维文蒂阿生物公司 用于肝细胞癌检测和治疗的组合物和方法
US9822182B2 (en) 2013-10-02 2017-11-21 Viventia Bio Inc. Anti-EPCAM antibodies and methods of use
US10576163B2 (en) 2015-03-12 2020-03-03 Viventia Bio Inc. Methods of treatment for EpCAM positive bladder cancer
US10583198B2 (en) 2015-03-12 2020-03-10 Viventia Bio Inc. Dosing strategies for targeting EPCAM positive bladder cancer

Similar Documents

Publication Publication Date Title
Di Paolo et al. A recombinant immunotoxin derived from a humanized epithelial cell adhesion molecule-specific single-chain antibody fragment has potent and selective antitumor activity
US11713351B2 (en) Immunotoxin for treating cancer
Reiter Recombinant immunotoxins in targeted cancer cell therapy
Fan et al. Therapeutic application of anti-growth factor receptor antibodies
Rosenblum et al. Design, expression, purification, and characterization, in vitro and in vivo, of an antimelanoma single-chain Fv antibody fused to the toxin gelonin
KR102099593B1 (ko) 항-인간 인터루킨-2 항체 및 이의 용도
MXPA04003535A (es) Proteinas de enlace para objetivos directos.
EP0590067A1 (fr) Fragments d'anticorps produits par des microbes et leurs conjugues
Wu et al. Recent development and optimization of pseudomonas aeruginosa exotoxin immunotoxins in cancer therapeutic applications
Pennell et al. Designing immunotoxins for cancer therapy
Schaedel et al. Antibodies and their fragments as anti-cancer agents
Li et al. Immunotoxins and cancer therapy
Kuan et al. Improved antitumor activity of a recombinant anti-Lewis (y) immunotoxin not requiring proteolytic activation.
Kreitman et al. Properties of chimeric toxins with two recognition domains: interleukin 6 and transforming growth factor. alpha. at different locations in Pseudomonas exotoxin
Pietersz et al. The genetic engineering of antibody constructs for diagnosis and therapy
CA2424255A1 (fr) Immunotoxines
EP1848462B1 (fr) Traitement du cancer à l'aide d'une immunotoxine comprenant une exotoxine a dont le site de clivage par la furine est remplacé par un site de protéase associée au cancer qui est clivé par mmp-2 ou mmp-9
Tur et al. An anti-GD2 single chain Fv selected by phage display and fused to Pseudomonas exotoxin A develops specific cytotoxic activity against neuroblastoma derived cell lines
Kreitman Recombinant immunotoxins for the treatment of haematological malignancies
Gottstein et al. Generation and characterization of recombinant vascular targeting agents from hybridoma cell lines
WO2024078612A1 (fr) Composé de charge utile et de lieur, conjugués et applications associées
Park et al. A divalent recombinant immunotoxin formed by a disulfide bond between the extension peptide chains
Rybak et al. Immunotoxins and beyond: targeted RNases
Ammon Development of Pseudomonas exotoxin-based duotoxins for the treatment of CD22 positive hematologic malignancies
CN116023501A (zh) 一种抗her2的免疫毒素分子、及其制备方法与应用

Legal Events

Date Code Title Description
FZDE Dead